Literature DB >> 22729431

Does the degree of hypothalamic-pituitary-ovarian recovery after oral contraceptive pills affect outcomes of IVF/ICSI cycles receiving GnRH-antagonist adjuvant therapy in women over 35 years of age?

Carla Schmitz1, Silvina Bocca, Hind Beydoun, Laurel Stadtmauer, Sergio Oehninger.   

Abstract

PURPOSE: To evaluate if the degree of recovery of serum gonadotropins after oral contraceptive pills (OCP) pretreatment has an impact on ovarian response in GnRH-antagonist IVF cycles in women of advanced maternal age.
METHODS: In this retrospective cohort study, we included 98 women 35-42 years undergoing their first IVF cycle receiving gonadotropins and a fixed GnRH-antagonist adjuvant protocol. Data analysis was carried out according to changes in serum FSH, LH and estradiol (E(2)) levels (basal and post-OCP) divided in quartiles, and also according to absolute levels. The main outcomes were peak serum E(2), number of mature oocytes retrieved, length of stimulation, and amount of gonadotropins used.
RESULTS: By quartile analysis, patients with the highest levels of serum gonadotropins suppression and also patients with gonadotropin rebound needed larger amounts of LH during the treatment. On the other hand, women with absolute suppression of FSH/LH had increased length of stimulation.
CONCLUSIONS: The results of this study provide data that assist in clinical management. Gonadotropin serum levels after OCP treatment provide information for optimization of supplementation with LH in GnRH-antagonist cycles in women over age 35.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22729431      PMCID: PMC3463673          DOI: 10.1007/s10815-012-9812-0

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  31 in total

1.  Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.

Authors:  A M van Heusden; B C Fauser
Journal:  Contraception       Date:  1999-04       Impact factor: 3.375

2.  Gonadotropin suppression with oral contraceptives before in vitro fertilization.

Authors:  Y Gonen; W Jacobson; R F Casper
Journal:  Fertil Steril       Date:  1990-02       Impact factor: 7.329

3.  High FSH:LH ratio and low LH levels in basal cycle day 3: impact on follicular development and IVF outcome.

Authors:  G Barroso; S Oehninger; A Monzó; P Kolm; W E Gibbons; S J Muasher
Journal:  J Assist Reprod Genet       Date:  2001-09       Impact factor: 3.412

4.  Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group.

Authors: 
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

5.  Is there an increased risk of twinning after discontinuation of the oral contraceptive pill?

Authors:  M F Murphy; M J Campbell; M Bone
Journal:  J Epidemiol Community Health       Date:  1989-09       Impact factor: 3.710

6.  Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women.

Authors:  N A Klein; D E Battaglia; V Y Fujimoto; G S Davis; W J Bremner; M R Soules
Journal:  J Clin Endocrinol Metab       Date:  1996-03       Impact factor: 5.958

7.  Extracorporeal maturation: Norfolk, 1984.

Authors:  L L Veeck
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

8.  IVF/ICSI outcome and serum LH concentration on day 1 of ovarian stimulation with recombinant FSH under pituitary suppression.

Authors:  S Bjercke; P Fedorcsak; T Abyholm; R Storeng; G Ertzeid; N Oldereid; A Omland; T Tanbo
Journal:  Hum Reprod       Date:  2005-05-26       Impact factor: 6.918

9.  Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome.

Authors:  R T Scott; J P Toner; S J Muasher; S Oehninger; S Robinson; Z Rosenwaks
Journal:  Fertil Steril       Date:  1989-04       Impact factor: 7.329

10.  Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles.

Authors:  Belen Acevedo; Marta Sanchez; Jose Luis Gomez; Jorge Cuadros; Elisabetta Ricciarelli; Eleuterio R Hernández
Journal:  Fertil Steril       Date:  2004-08       Impact factor: 7.329

View more
  1 in total

1.  Pretreatment with oral contraceptive pills to identify poor responders that may benefit from rLH supplementation during GnRH-antagonist treatment for IVF: A pilot perspective study proposal.

Authors:  Salvatore Gizzo; Alessandra Andrisani; Marco Noventa; Michele Gangemi; Giovanni Battista Nardelli; Guido Ambrosini
Journal:  Exp Ther Med       Date:  2015-09-08       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.